Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
AssigneeIdorsia Pharmaceuticals Ltd
InventorsChristoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Markus Von Raumer, Jodi T. Williams
Life of this patent
Estimating the term…
Abstract
The invention relates to a crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride, processes for the preparation thereof, pharmaceutical compositions containing said crystalline form, and its use as medicament, especially as orexin receptor antagonist.
Claims6
A crystalline form of the compound (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazole-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone;
- wherein said compound is present in form of the hydrochloric acid salt;
- wherein said crystalline salt form comprises peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ:
- 11.0°, 24.1° and 24.5°, wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping;
- and the accuracy of the 2θ values is in the range of 2θ+/−0.2°.
Dependencies are inferred from the claim text.